Radius Health Inc (RDUS) 64.23 $RDUS
Jim Cramer -- Allergan May Get a Higher Bid from Pfizer; Biotech to Buy
at The Street - Thu Oct 29, 1:25PM CDT
From the floor of the New York Stock Exchange, TheStreet's Jim Cramer takes viewer questions posted on Twitter. He looks at Allergan, Pfizer and other stocks.
BIIB: 290.51 (-3.21), GPRO: 25.00 (-0.62), SWKS: 77.24 (+2.61), FB: 101.97 (-2.91), AVT: 45.43 (+0.62), PFE: 33.82 (-0.95), VFC: 67.52 (-0.59), M: 50.98 (+1.28), AMGN: 158.18 (-2.40), LLY: 81.57 (-0.43), BMY: 65.95 (-1.36), NXPI: 78.35 (+5.35), INTC: 33.86 (-0.17), CELG: 122.71 (-2.22), AGN: 308.47 (+4.09), RDUS: 64.23 (+1.19), WBA: 84.68 (+0.80), QRVO: 43.93 (+0.12), TXN: 56.72 (+0.15), TGT: 77.18 (+0.90), ADI: 60.12 (+0.14), TWTR: 28.46 (-0.60), AAPL: 119.50 (-1.03), AVGO: 123.13 (+3.04)
Radius Health to Announce Third Quarter 2015 Financial Results, Host Conference Call and Live Webcast on November 5, 2015
GlobeNewswire - Wed Oct 28, 4:26PM CDT
Radius Health (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive metastatic breast cancer, announced today that it will release its third quarter 2015 financial results on Thursday, November 5, 2015.
RDUS: 64.23 (+1.19)
Jim Cramer -- Microsoft, IBM Should Have Their Eyes on the Buys
at The Street - Tue Oct 20, 1:20PM CDT
If you ask Jim Cramer (and social media users did), Microsoft should acquire Salesforce, IBM should grab Box, pharmaceuticals have a political problem, and there's no substitute for Berkshire Hathaway.
WFM: 29.96 (-0.19), VRX: 93.77 (-17.73), BOX: 12.48 (-0.01), TREE: 121.36 (-1.15), TFM: 24.92 (-0.16), PSTG: 17.63 (-0.18), WFC: 54.14 (-0.95), MKL: 868.00 (-9.87), WWAV: 40.98 (+0.74), RDUS: 64.23 (+1.19), LEN: 50.07 (+0.81), IBM: 140.08 (-0.47), HZNP: 15.72 (-1.77), WY: 29.33 (+0.16), MSFT: 52.64 (-0.72), TOL: 35.97 (+0.40), BRK.A: 204,596.00 (-2,220.91), CRM: 77.71 (-0.43)
Why Radius Health Inc is Soaring Today
Brian Feroldi, The Motley Fool - Motley Fool - Thu Oct 15, 3:02PM CDT
What: Shares of Radius Health , a biopharmaceutical company focused on developing products that treat osteoporosis and other endocrine-mediated diseases, were up more than 17% on huge trading volume on what appear to be rumors of a possible...
RDUS: 64.23 (+1.19), SHPG: 227.05 (+0.53)
Radius Health (RDUS) Looks Good: Stock Rises 8.7%
Zacks Equity Research - Zacks Investment Research - Thu Oct 15, 7:30AM CDT
Radius Health, Inc. (RDUS) was a big mover last session, as the company saw its shares rise roughly 9% on the day.
RDUS: 64.23 (+1.19), ENDP: 59.99 (-0.39)
Radius (RDUS) Reports Positive Data on Osteoporosis Drug
Zacks Equity Research - Zacks Investment Research - Mon Oct 12, 3:40PM CDT
Radius Health, Inc. (RDUS) presented positive top-line data from the phase III ACTIVE study on its lead candidate abaloparatide - subcutaneous.
RDUS: 64.23 (+1.19), ANAC: 112.41 (+7.08), LLY: 81.57 (-0.43), ANIK: 38.52 (-0.55)
Investigational Drug Abaloparatide Reduces the Incidence of Fractures in Postmenopausal Women With Osteoporosis
GlobeNewswire - Mon Oct 12, 1:30PM CDT
Radius Health announces positive Phase 3 data from the ACTIVExtend trial presented at the American Society for Bone and Mineral Research (ASBMR) 2015 Annual Meeting
RDUS: 64.23 (+1.19)
Radius Health Presents Positive Phase 3 Top-Line Data for Investigational Osteoporosis Therapy Abaloparatide at the American Society for Bone and Mineral Research 2015 Annual Meeting
GlobeNewswire - Sat Oct 10, 6:15PM CDT
Radius Health, Inc. (Nasdaq:RDUS) announces positive top-line data from the Phase 3 ACTIVE (Abaloparatide Comparator Trial In Vertebral Endpoints) trial, which showed that women with postmenopausal osteoporosis (PMO) who received 18 months of daily abaloparatide (ABL) subcutaneous (SC) injection experienced a 70 percent reduction in the incidence of major osteoporotic fractures compared to placebo. Responder analysis showed greater increases in bone mineral density (BMD) at three combined anatomical sites (total hip, femoral neck and lumbar spine) compared to placebo or teriparatide (TPTD) at 6, 12 and 18 months. These results, along with positive pharmacokinetic data from a study evaluating the ABL transdermal patch, were presented during the American Society for Bone and Mineral Research (ASBMR) 2015 Annual Meeting as oral and poster presentations, respectively.
RDUS: 64.23 (+1.19)
'Mad Money' Lightning Round: Buy AT&T, Verizon, Walgreens Boots Alliance
at The Street - Sat Oct 10, 5:00AM CDT
Cramer says you have to be willing to take some pain on Radius Health and GW Pharmaceuticals.
RDUS: 64.23 (+1.19), GLNG: 29.01 (+0.48), CI: 134.04 (-1.51), T: 33.51 (-0.04), WBA: 84.68 (+0.80), ETP: 44.16 (+0.15), GWPH: 79.09 (-1.87), LNG: 49.52 (+0.52), QSII: 14.05 (-0.25), VZ: 46.88 (+0.48), HSIC: 151.71 (+0.84)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Oct 09, 6:45PM CDT
It's government shutdown season and that's never good for the stock market, Cramer says. So he'll be watching Washington as well as earnings from Johnson & Johnson and Wells Fargo.
GE: 28.92 (-0.42), HON: 103.28 (+0.34), DAL: 50.84 (+0.34), C: 53.17 (-0.49), PSTG: 17.63 (-0.18), QSII: 14.05 (-0.25), INTC: 33.86 (-0.17), SLB: 78.16 (-0.53), JNJ: 101.03 (-0.34), T: 33.51 (-0.04), ETP: 44.16 (+0.15), JPM: 64.25 (-0.96), GWPH: 79.09 (-1.87), HSIC: 151.71 (+0.84), GLNG: 29.01 (+0.48), LNG: 49.52 (+0.52), WFC: 54.14 (-0.95), BAC: 16.78 (-0.31), LLY: 81.57 (-0.43), BMY: 65.95 (-1.36), CSX: 26.99 (-0.26), CI: 134.04 (-1.51), RDUS: 64.23 (+1.19), WBA: 84.68 (+0.80), GS: 187.50 (-2.39), VZ: 46.88 (+0.48)
'Mad Money' Lightning Round: IBM Is Getting Attractive
at The Street - Fri Sep 25, 5:00AM CDT
Cramer says Radius Health is terrific but Blue Buffalo Pet Products is expensive compared to its growth rate.
RDUS: 64.23 (+1.19),
71.43 (+0.55), YHOO: 35.62 (+0.57), CY: 10.54 (+0.66), WTR: 28.60 (+0.29), SNR: 10.02 (+0.01), IBM: 140.08 (-0.47), ED: 65.75 (+0.41), HUN: 13.17 (-0.04), BUFF: 17.94 (+0.01), BABA: 83.83 (+1.61)
Jim Cramer's 'Mad Money' Recap: Don't Take It Personal but Your Stocks Are Going Down
at The Street - Thu Sep 24, 6:57PM CDT
It's not that you haven't picked great stocks, the market just stinks and is acting irrationally, Cramer confides.
71.43 (+0.55), CY: 10.54 (+0.66), CCL: 54.08 (unch), ED: 65.75 (+0.41), LLY: 81.57 (-0.43), TKR: 31.60 (+0.54), BA: 148.07 (+0.89), HUN: 13.17 (-0.04), BUFF: 17.94 (+0.01), DRI: 61.89 (-0.54), RDUS: 64.23 (+1.19), YHOO: 35.62 (+0.57), WTR: 28.60 (+0.29), TMST: 10.64 (-0.06), AZO: 784.41 (+1.18), SNR: 10.02 (+0.01), OPK: 9.45 (+0.06), IBM: 140.08 (-0.47), MRK: 54.66 (-0.21), CAT: 72.99 (+1.02), BABA: 83.83 (+1.61)
Radius Health, Inc. Announces Webcast on Investigational Drug RAD1901, Upcoming Presentations and Investor Day in New York City on November 17th, 2015
GlobeNewswire - Tue Sep 22, 4:13PM CDT
Radius Health, Inc. ("Radius" or the "Company"
(Nasdaq:RDUS) announced today that it plans to host a conference call and webcast on Thursday, September 24, 2015, to provide an update on the safety and tolerability profile of RAD1901, a selective estrogen receptor degrader, from the completed Phase I study of RAD1901 in 52 healthy volunteers.
RDUS: 64.23 (+1.19)
Biotechnology Equities under Review -- Radius Health, Hemispherx Biopharma, Seattle Genetics, Spectrum Pharma and Vanda Pharma
PR Newswire - Tue Sep 15, 7:40AM CDT
Equity Research Institute has initiated coverage on the following equities: Radius Health Inc. (NASDAQ: RDUS), Hemispherx Biopharma Inc. (AMEX: HEB), Seattle Genetics Inc. (NASDAQ: SGEN), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI) and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA). Free research report on Radius Health can be accessed at https://www.erionline.net/reports?keyword=RDUS. On Monday, September 14, 2015, the NASDAQ Composite ended at 4,805.76, down 0.34%, the Dow Jones Industrial Average edged 0.38% lower, to finish the day at 16,370.96 and the S&P 500 closed at 1,953.03, down 0.41%. The losses were broad based as eight out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
RDUS: 64.23 (+1.19), SGEN: 41.49 (-0.65), HEB: 0.13 (unch), VNDA: 10.74 (-0.35), SPPI: 5.21 (+0.10)
Radius Health Announced That it Has Appointed Catherine Friedman to the Board of Directors
GlobeNewswire - Tue Aug 18, 6:00AM CDT
Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive metastatic breast cancer, today announced that Catherine Friedman, an independent consultant and former Co-Head of the Biotechnology Practice at Morgan Stanley, has been elected to its Board of Directors. Cathy has also been appointed Chair of the Audit Committee of the Board of Directors, replacing Dr. Muenchbach, who has resigned from the Board effective November 3, 2015, but will remain on the Board until that date in order to ensure a smooth transition.
RDUS: 64.23 (+1.19)
Jim Cramer's Top Takeaways: Radius Health, Inovio Pharmaceuticals
at The Street - Tue Aug 11, 5:00AM CDT
Cramer says Radius Health offers investors multiple ways to win.
RDUS: 64.23 (+1.19), INO: 6.33 (-0.13), AZN: 31.89 (-0.35)
'Mad Money' Lightning Round: Buy, Buy, Buy MGM Resorts
at The Street - Tue Aug 11, 5:00AM CDT
Cramer likes Enterprise Products Partners, says Dave and Busters is in a tough business and thinks Helen of Troy should be higher.
RDUS: 64.23 (+1.19), HELE: 99.21 (-0.38), PLAY: 38.58 (-0.19), MGM: 23.19 (+0.39), MDXG: 7.28 (-0.01), EPD: 27.63 (+0.02)
Jim Cramer's 'Mad Money' Recap: 10 Things That Created Today's Market Rally
at The Street - Mon Aug 10, 7:23PM CDT
Warren Buffett was one reason for the rally, Cramer says. Here are nine more.
SNA: 165.89 (+1.09), L: 36.46 (-0.34), XOM: 82.74 (+0.51), CB: 129.35 (-1.33), PCP: 230.81 (-0.20), ETR: 68.16 (+0.66), INO: 6.33 (-0.13), DO: 19.88 (+0.36), AMAT: 16.77 (+0.03), GOOGL: 737.39 (-7.46), HSIC: 151.71 (+0.84), AAPL: 119.50 (-1.03), MDXG: 7.28 (-0.01), SE: 28.57 (+0.08), MGM: 23.19 (+0.39), WWAV: 40.98 (+0.74), HELE: 99.21 (-0.38), NFLX: 108.38 (+3.26), RDUS: 64.23 (+1.19), AA: 8.93 (-0.02), LEN: 50.07 (+0.81), AZN: 31.89 (-0.35), PLAY: 38.58 (-0.19), PG: 76.38 (-0.64), GIS: 58.11 (-0.07), EPD: 27.63 (+0.02)
Radius Health Q2 Loss Wider than Expected, Narrower Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 07, 5:21PM CDT
Radius Health (RDUS) reported a loss of 61 cents per share in the second-quarter of 2015, wider than the Zacks Consensus Estimate of a loss of 50 cents.
RDUS: 64.23 (+1.19), VRX: 93.77 (-17.73), ANAC: 112.41 (+7.08), CORT: 3.69 (-0.10)
Radius Health (RDUS) Posts Wider-Than-Expected Q2 Loss - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 06, 6:46AM CDT
Radius Health (RDUS) Posts Wider-Than-Expected Q2 Loss
RDUS: 64.23 (+1.19)
Jim Cramer -- Allergan May Get a Higher Bid from Pfizer; Biotech to Buy
at The Street - Thu Oct 29, 1:25PM CDT
From the floor of the New York Stock Exchange, TheStreet's Jim Cramer takes viewer questions posted on Twitter. He looks at Allergan, Pfizer and other stocks.
BIIB: 290.51 (-3.21), GPRO: 25.00 (-0.62), SWKS: 77.24 (+2.61), FB: 101.97 (-2.91), AVT: 45.43 (+0.62), PFE: 33.82 (-0.95), VFC: 67.52 (-0.59), M: 50.98 (+1.28), AMGN: 158.18 (-2.40), LLY: 81.57 (-0.43), BMY: 65.95 (-1.36), NXPI: 78.35 (+5.35), INTC: 33.86 (-0.17), CELG: 122.71 (-2.22), AGN: 308.47 (+4.09), RDUS: 64.23 (+1.19), WBA: 84.68 (+0.80), QRVO: 43.93 (+0.12), TXN: 56.72 (+0.15), TGT: 77.18 (+0.90), ADI: 60.12 (+0.14), TWTR: 28.46 (-0.60), AAPL: 119.50 (-1.03), AVGO: 123.13 (+3.04)
Radius Health to Announce Third Quarter 2015 Financial Results, Host Conference Call and Live Webcast on November 5, 2015
GlobeNewswire - Wed Oct 28, 4:26PM CDT
Radius Health (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive metastatic breast cancer, announced today that it will release its third quarter 2015 financial results on Thursday, November 5, 2015.
RDUS: 64.23 (+1.19)
Jim Cramer -- Microsoft, IBM Should Have Their Eyes on the Buys
at The Street - Tue Oct 20, 1:20PM CDT
If you ask Jim Cramer (and social media users did), Microsoft should acquire Salesforce, IBM should grab Box, pharmaceuticals have a political problem, and there's no substitute for Berkshire Hathaway.
WFM: 29.96 (-0.19), VRX: 93.77 (-17.73), BOX: 12.48 (-0.01), TREE: 121.36 (-1.15), TFM: 24.92 (-0.16), PSTG: 17.63 (-0.18), WFC: 54.14 (-0.95), MKL: 868.00 (-9.87), WWAV: 40.98 (+0.74), RDUS: 64.23 (+1.19), LEN: 50.07 (+0.81), IBM: 140.08 (-0.47), HZNP: 15.72 (-1.77), WY: 29.33 (+0.16), MSFT: 52.64 (-0.72), TOL: 35.97 (+0.40), BRK.A: 204,596.00 (-2,220.91), CRM: 77.71 (-0.43)
Why Radius Health Inc is Soaring Today
Brian Feroldi, The Motley Fool - Motley Fool - Thu Oct 15, 3:02PM CDT
What: Shares of Radius Health , a biopharmaceutical company focused on developing products that treat osteoporosis and other endocrine-mediated diseases, were up more than 17% on huge trading volume on what appear to be rumors of a possible...
RDUS: 64.23 (+1.19), SHPG: 227.05 (+0.53)
Radius Health (RDUS) Looks Good: Stock Rises 8.7%
Zacks Equity Research - Zacks Investment Research - Thu Oct 15, 7:30AM CDT
Radius Health, Inc. (RDUS) was a big mover last session, as the company saw its shares rise roughly 9% on the day.
RDUS: 64.23 (+1.19), ENDP: 59.99 (-0.39)
Radius (RDUS) Reports Positive Data on Osteoporosis Drug
Zacks Equity Research - Zacks Investment Research - Mon Oct 12, 3:40PM CDT
Radius Health, Inc. (RDUS) presented positive top-line data from the phase III ACTIVE study on its lead candidate abaloparatide - subcutaneous.
RDUS: 64.23 (+1.19), ANAC: 112.41 (+7.08), LLY: 81.57 (-0.43), ANIK: 38.52 (-0.55)
Investigational Drug Abaloparatide Reduces the Incidence of Fractures in Postmenopausal Women With Osteoporosis
GlobeNewswire - Mon Oct 12, 1:30PM CDT
Radius Health announces positive Phase 3 data from the ACTIVExtend trial presented at the American Society for Bone and Mineral Research (ASBMR) 2015 Annual Meeting
RDUS: 64.23 (+1.19)
Radius Health Presents Positive Phase 3 Top-Line Data for Investigational Osteoporosis Therapy Abaloparatide at the American Society for Bone and Mineral Research 2015 Annual Meeting
GlobeNewswire - Sat Oct 10, 6:15PM CDT
Radius Health, Inc. (Nasdaq:RDUS) announces positive top-line data from the Phase 3 ACTIVE (Abaloparatide Comparator Trial In Vertebral Endpoints) trial, which showed that women with postmenopausal osteoporosis (PMO) who received 18 months of daily abaloparatide (ABL) subcutaneous (SC) injection experienced a 70 percent reduction in the incidence of major osteoporotic fractures compared to placebo. Responder analysis showed greater increases in bone mineral density (BMD) at three combined anatomical sites (total hip, femoral neck and lumbar spine) compared to placebo or teriparatide (TPTD) at 6, 12 and 18 months. These results, along with positive pharmacokinetic data from a study evaluating the ABL transdermal patch, were presented during the American Society for Bone and Mineral Research (ASBMR) 2015 Annual Meeting as oral and poster presentations, respectively.
RDUS: 64.23 (+1.19)
'Mad Money' Lightning Round: Buy AT&T, Verizon, Walgreens Boots Alliance
at The Street - Sat Oct 10, 5:00AM CDT
Cramer says you have to be willing to take some pain on Radius Health and GW Pharmaceuticals.
RDUS: 64.23 (+1.19), GLNG: 29.01 (+0.48), CI: 134.04 (-1.51), T: 33.51 (-0.04), WBA: 84.68 (+0.80), ETP: 44.16 (+0.15), GWPH: 79.09 (-1.87), LNG: 49.52 (+0.52), QSII: 14.05 (-0.25), VZ: 46.88 (+0.48), HSIC: 151.71 (+0.84)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Oct 09, 6:45PM CDT
It's government shutdown season and that's never good for the stock market, Cramer says. So he'll be watching Washington as well as earnings from Johnson & Johnson and Wells Fargo.
GE: 28.92 (-0.42), HON: 103.28 (+0.34), DAL: 50.84 (+0.34), C: 53.17 (-0.49), PSTG: 17.63 (-0.18), QSII: 14.05 (-0.25), INTC: 33.86 (-0.17), SLB: 78.16 (-0.53), JNJ: 101.03 (-0.34), T: 33.51 (-0.04), ETP: 44.16 (+0.15), JPM: 64.25 (-0.96), GWPH: 79.09 (-1.87), HSIC: 151.71 (+0.84), GLNG: 29.01 (+0.48), LNG: 49.52 (+0.52), WFC: 54.14 (-0.95), BAC: 16.78 (-0.31), LLY: 81.57 (-0.43), BMY: 65.95 (-1.36), CSX: 26.99 (-0.26), CI: 134.04 (-1.51), RDUS: 64.23 (+1.19), WBA: 84.68 (+0.80), GS: 187.50 (-2.39), VZ: 46.88 (+0.48)
'Mad Money' Lightning Round: IBM Is Getting Attractive
at The Street - Fri Sep 25, 5:00AM CDT
Cramer says Radius Health is terrific but Blue Buffalo Pet Products is expensive compared to its growth rate.
RDUS: 64.23 (+1.19),
71.43 (+0.55), YHOO: 35.62 (+0.57), CY: 10.54 (+0.66), WTR: 28.60 (+0.29), SNR: 10.02 (+0.01), IBM: 140.08 (-0.47), ED: 65.75 (+0.41), HUN: 13.17 (-0.04), BUFF: 17.94 (+0.01), BABA: 83.83 (+1.61) Jim Cramer's 'Mad Money' Recap: Don't Take It Personal but Your Stocks Are Going Down
at The Street - Thu Sep 24, 6:57PM CDT
It's not that you haven't picked great stocks, the market just stinks and is acting irrationally, Cramer confides.
71.43 (+0.55), CY: 10.54 (+0.66), CCL: 54.08 (unch), ED: 65.75 (+0.41), LLY: 81.57 (-0.43), TKR: 31.60 (+0.54), BA: 148.07 (+0.89), HUN: 13.17 (-0.04), BUFF: 17.94 (+0.01), DRI: 61.89 (-0.54), RDUS: 64.23 (+1.19), YHOO: 35.62 (+0.57), WTR: 28.60 (+0.29), TMST: 10.64 (-0.06), AZO: 784.41 (+1.18), SNR: 10.02 (+0.01), OPK: 9.45 (+0.06), IBM: 140.08 (-0.47), MRK: 54.66 (-0.21), CAT: 72.99 (+1.02), BABA: 83.83 (+1.61) Radius Health, Inc. Announces Webcast on Investigational Drug RAD1901, Upcoming Presentations and Investor Day in New York City on November 17th, 2015
GlobeNewswire - Tue Sep 22, 4:13PM CDT
Radius Health, Inc. ("Radius" or the "Company"
(Nasdaq:RDUS) announced today that it plans to host a conference call and webcast on Thursday, September 24, 2015, to provide an update on the safety and tolerability profile of RAD1901, a selective estrogen receptor degrader, from the completed Phase I study of RAD1901 in 52 healthy volunteers. RDUS: 64.23 (+1.19)
Biotechnology Equities under Review -- Radius Health, Hemispherx Biopharma, Seattle Genetics, Spectrum Pharma and Vanda Pharma
PR Newswire - Tue Sep 15, 7:40AM CDT
Equity Research Institute has initiated coverage on the following equities: Radius Health Inc. (NASDAQ: RDUS), Hemispherx Biopharma Inc. (AMEX: HEB), Seattle Genetics Inc. (NASDAQ: SGEN), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI) and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA). Free research report on Radius Health can be accessed at https://www.erionline.net/reports?keyword=RDUS. On Monday, September 14, 2015, the NASDAQ Composite ended at 4,805.76, down 0.34%, the Dow Jones Industrial Average edged 0.38% lower, to finish the day at 16,370.96 and the S&P 500 closed at 1,953.03, down 0.41%. The losses were broad based as eight out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
RDUS: 64.23 (+1.19), SGEN: 41.49 (-0.65), HEB: 0.13 (unch), VNDA: 10.74 (-0.35), SPPI: 5.21 (+0.10)
Radius Health Announced That it Has Appointed Catherine Friedman to the Board of Directors
GlobeNewswire - Tue Aug 18, 6:00AM CDT
Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive metastatic breast cancer, today announced that Catherine Friedman, an independent consultant and former Co-Head of the Biotechnology Practice at Morgan Stanley, has been elected to its Board of Directors. Cathy has also been appointed Chair of the Audit Committee of the Board of Directors, replacing Dr. Muenchbach, who has resigned from the Board effective November 3, 2015, but will remain on the Board until that date in order to ensure a smooth transition.
RDUS: 64.23 (+1.19)
Jim Cramer's Top Takeaways: Radius Health, Inovio Pharmaceuticals
at The Street - Tue Aug 11, 5:00AM CDT
Cramer says Radius Health offers investors multiple ways to win.
RDUS: 64.23 (+1.19), INO: 6.33 (-0.13), AZN: 31.89 (-0.35)
'Mad Money' Lightning Round: Buy, Buy, Buy MGM Resorts
at The Street - Tue Aug 11, 5:00AM CDT
Cramer likes Enterprise Products Partners, says Dave and Busters is in a tough business and thinks Helen of Troy should be higher.
RDUS: 64.23 (+1.19), HELE: 99.21 (-0.38), PLAY: 38.58 (-0.19), MGM: 23.19 (+0.39), MDXG: 7.28 (-0.01), EPD: 27.63 (+0.02)
Jim Cramer's 'Mad Money' Recap: 10 Things That Created Today's Market Rally
at The Street - Mon Aug 10, 7:23PM CDT
Warren Buffett was one reason for the rally, Cramer says. Here are nine more.
SNA: 165.89 (+1.09), L: 36.46 (-0.34), XOM: 82.74 (+0.51), CB: 129.35 (-1.33), PCP: 230.81 (-0.20), ETR: 68.16 (+0.66), INO: 6.33 (-0.13), DO: 19.88 (+0.36), AMAT: 16.77 (+0.03), GOOGL: 737.39 (-7.46), HSIC: 151.71 (+0.84), AAPL: 119.50 (-1.03), MDXG: 7.28 (-0.01), SE: 28.57 (+0.08), MGM: 23.19 (+0.39), WWAV: 40.98 (+0.74), HELE: 99.21 (-0.38), NFLX: 108.38 (+3.26), RDUS: 64.23 (+1.19), AA: 8.93 (-0.02), LEN: 50.07 (+0.81), AZN: 31.89 (-0.35), PLAY: 38.58 (-0.19), PG: 76.38 (-0.64), GIS: 58.11 (-0.07), EPD: 27.63 (+0.02)
Radius Health Q2 Loss Wider than Expected, Narrower Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 07, 5:21PM CDT
Radius Health (RDUS) reported a loss of 61 cents per share in the second-quarter of 2015, wider than the Zacks Consensus Estimate of a loss of 50 cents.
RDUS: 64.23 (+1.19), VRX: 93.77 (-17.73), ANAC: 112.41 (+7.08), CORT: 3.69 (-0.10)
Radius Health (RDUS) Posts Wider-Than-Expected Q2 Loss - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 06, 6:46AM CDT
Radius Health (RDUS) Posts Wider-Than-Expected Q2 Loss
RDUS: 64.23 (+1.19)
